Scheduling of anticancer drugs: Timing may be everything

Cell Cycle

Volumn 11, Issue 23, 2012, Pages 4339-4343

  Van Der Veldt, Astrid A M ^a   Lammertsma, Adriaan A ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticancer drugs; Drug scheduling; Oncology; Positron emission tomography; Radiolabeled drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; OXYGEN 15; PACLITAXEL; TAMOXIFEN; VERAPAMIL;

BREAST CANCER; COLORECTAL CANCER; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG MECHANISM; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 84870909761     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22187     Document Type: Review

References (49)

1. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, et al. Network modeling of MDM2 inhibitoroxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011; 2:378-92; PMID:21623005.
2. Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, et al. Scheduledependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 2011; 10:3119-28; PMID:21900747; http://dx.doi.org/10.4161/cc.10.18.17190.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/ NEJMoa060655.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76; PMID:18160686; http://dx.doi.org/10. 1056/NEJMoa072113.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044.
7. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/ NEJMoa061884.
8. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-8; PMID:20100962; http://dx.doi.org/10.1200/JCO.2009.23.9764.
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-34; PMID:12890841; http://dx.doi.org/10.1056/NEJMoa021491.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-95; PMID:10742145; http://dx.doi.org/10.1038/74651.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http://dx.doi.org/10.1016/S0092-8674(00)81683-9.
12. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74; PMID:16355214; http://dx.doi.org/10.1038/nature04483.
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603-669.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400; PMID:15136787; http://dx.doi.org/10.1038/nrd1381.
15. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966-72; PMID:19720913; http://dx.doi.org/10.1200/JCO.2008.21.6630.
16. Proposal to Withdraw Approval for the Breast Cancer Indication for AVASTIN (Bevacizumab). www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf.
17. Montero AJ, Vogel C. Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 2012; 366:374-5; PMID:22276827; http://dx.doi.org/10.1056/ NEJMe1113368.
18. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-93; PMID:12209157; http://dx.doi.org/10. 1038/nrc882.
19. van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008; 14:2914-31; PMID:18991710; http://dx.doi.org/10.2174/138161208786404344.
20. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Möhler M, Oberdorfer F, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39:1197-202; PMID:9669393.
21. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-f luorouracil. Cancer 1998; 83:245-53; PMID:9669806; http://dx.doi.org/ 10.1002/(SICI)1097-0142(19980715)83:2〈245::AIDCNCR7〉 3.0.CO;2-P.
22. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996; 11:235-45; PMID:10851543; http://dx.doi.org/10.1089/cbr.1996.11.235.
23. van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, et al. Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography. Clin Cancer Res 2011; 17:4814-24; PMID:21750197; http://dx.doi.org/10.1158/1078-0432.CCR-10-2933.
24. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61:4937-41; PMID:11431319.
25. Bading JR, Alauddin MM, Fissekis JD, Shahinian AH, Joung J, Spector T, et al. Blocking catabolism with eniluracil enhances PET studies of 5-[18F] fluorouracil pharmacokinetics. J Nucl Med 2000; 41:1714-24; PMID:11038003.
26. Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D'Argenio DZ, Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 2003; 63:3667-74; PMID:12839957.
27. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355:2125-31; PMID:10902627; http://dx.doi.org/10.1016/ S0140-6736(00)02380-1.
28. Gupta N, Saleem A, Kötz B, Osman S, Aboagye EO, Phillips R, et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 2006; 12:3115-23; PMID:16707610; http://dx.doi.org/10.1158/1078-0432. CCR-05-0513.
29. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17:1580-8; PMID:10334547.
30. Bomber P, McCready R, Hammersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake of gallium-67 in a mouse sarcoma. J Nucl Med 1986; 27:243-5; PMID:3712042.
31. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2011; 2:797-809; PMID:22006582.
32. van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010; 51:1684-90; PMID:20956480; http://dx.doi.org/10.2967/jnumed.110.079137.
33. Flower MA, Zweit J, Hall AD, Burke D, Davies MM, Dworkin MJ, et al. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med 2001; 28:99-103; PMID:11202458; http://dx.doi.org/10.1007/s002590000410.
34. Koh T, Taniguchi H, Yamagishi H. Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin II-induced hypertension. Cancer Chemother Pharmacol 2003; 51:349-58; PMID:12721763.
35. Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, et al. Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 1996; 37:1522-3; PMID:8790207.
36. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21:82-91; PMID:22264790; http://dx.doi.org/10.1016/j.ccr.2011.11.023.
37. Zissen MH, Kunz P, Subbarayan M, Chin FT, Conti PS, Fisher GA, et al. 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. Nucl Med Commun 2011; 32:343-7; PMID:21412178; http://dx.doi.org/10.1097/MNM. 0b013e328344894b.
38. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012; 109:2784-9; PMID:22308314; http://dx.doi.org/10.1073/pnas.1018866109.
39. Conley SJ, Wicha MS. Antiangiogenic agents: fueling cancer's hypoxic roots. Cell Cycle 2012; 11:1265-6; PMID:22421155; http://dx.doi.org/10.4161/cc. 19890.
40. Casanovas O. Cancer: Limitations of therapies exposed. Nature 2012; 484:44-6; PMID:22481354; http://dx.doi.org/10.1038/484044a.
41. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232:643-5; PMID:3457471; http://dx.doi.org/10.1126/ science.3457471.
42. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40(Suppl):S13-9; PMID:9272128; http://dx.doi.org/10.1007/s002800051055.
43. Lin JH. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 2003; 55:53-81; PMID:12535574; http://dx.doi.org/10.1016/S0169-409X(02)00171-0.
44. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21:25-51; PMID:14706810; http://dx.doi.org/10.1016/j.ejps.2003.07. 003.
45. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000; 6:2598-603; PMID:10914699.
46. Conti PS, Keppler JS, Halls JM. Positron emission tomography: a financial and operational analysis. AJR Am J Roentgenol 1994; 162:1279-86; PMID:8191981.
47. Keppler JS, Conti PS. A cost analysis of positron emission tomography. AJR Am J Roentgenol 2001; 177:31-40; PMID:11418393.
48. van der Veldt AA, Smit EF. Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 2012; 366:1637-40, author reply 1638-40; PMID:22533581; http://dx.doi.org/10.1056/NEJMc1202229.
49. Wang ES, Pili R, Seshadri M. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 2012; 30:760-1, author reply 761-3; PMID:22291088; http://dx.doi.org/10.1200/ JCO.2011.39.3934.